Accelerate time to clinic for advanced therapies with a platform approach

Cell & Gene Therapy Insights 2024; 10(3), 297;

DOI: 10.18609/cgti.2024.044

Published: 16 April
John Lee, Cédrick Rousseaux, Dana Cipriano

Watch the video or view the poster to learn about:

  • Considerations underpinning robust platform design tailored for the unique challenges of cell and gene therapies
  • Key features and integrations to enhance process and production efficiency
  • Recommendations for end-to-end offering for plasmid production, viral vector manufacturing, cell therapy processing, and in-process and release analytics

John Lee is an accomplished CAR-T immunobiologist with over 20 years of cancer cell biology expertise spanning small and large molecules, as well as cell-based therapeutics. He possesses more than 15 years of clinical research and cell therapy experience including positions at The Wistar Institute, Janssen Pharmaceuticals, and GlaxoSmithKline. Lee previously built the Cell Therapy Platform team at Janssen Pharmaceuticals. The group led and supported end-to-end therapy discovery and development across nearly a dozen CAR-T programs, including the recently approved cilta-cel (Carvykti). Lee holds a PhD from the Brody School of Medicine, an MBA from Penn State University, and a BSc from Indiana University of Pennsylvania.

Cédrick Rousseaux held several positions in Tech transfer and Process Development since he joined the company in 2015. Cédrick has worked in the medical device field for more than 15 years before joining SK pharmteco and held several jobs in cGMP manufacturing as well as in analytical or process tech transfer. Cedrick holds a MSc in Cellular and Molecular Engineering from Lille University.

Dana Cipriano has over a 20-year career in biotechnology and cell and gene therapy with leadership roles in Laboratory Operations and Project Management, with focus on designing processes and testing programs to drive sustainable growth and profitability. She was most recently Senior Director of Testing Operations and Strategic Projects for WuXi Advanced Therapies. Dana developed a fully-integrated program for development of a new corporate strategy centered on driving scalability in cell and gene therapy testing services, including design and construction of a new cGMP testing facility. Dana has a MSc in Microbiology from Thomas Jefferson University, a Bsc in Biology from Rutgers University, an Executive Education Certification from The Wharton School, and a PMP (Project Management Professional) certification.